Brimonidine EP Impurity G

Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma
B.Chianga1Y.C.Kimb1A.C.Dotyc12H.E.GrossniklausdS.P.SchwendemancM.R.Prausnitz
Journal of Controlled Release Volume 228, 28 April 2016, Pages 48-57
 
Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma
Jianguo Sun, Yuan Lei, Zhaoxing Dai∥, Xi Liu, Taomin Huang, Jihong Wu, Zhi Ping XOrcid, and Xinghuai Sun
ACS Appl. Mater. Interfaces 2017, 9, 9, 7990–7999
 
A validated stability-indicating HPLC method for determination of brimonidine tartrate in BRI/PHEMA drug delivery systems
Jianguo Sun, Xiuwen Zhang & Taomin Huang
Chemistry Central Journal volume 11, Article number: 62 (2017)
 
Development and Validation of Stability Indicating UV Spectrophotometric Method for the Estimation of Brimonidine Tartrate in Pure Form, Formulations and Preformulation Studies
Prakash Bhagav 1, Pandurang Deshpande 1, Saurabh Pandey 1 , Sajeev Chandran
Der Pharmacia Lettre, 2010, 2(3): 106-122

Brimonidine EP Impurity G is chemically 1-(2-Aminoethyl)-3-(5-bromoquinoxalin-6-yl)urea. Brimonidine EP Impurity G is supplied with detailed characterization data compliant with regulatory guideline. Brimonidine EP Impurity G can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Brimonidine.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.